Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo

Abstract excerpt

Abstract Background Multidrug resistance (MDR) is a complex phenomenon that frequently leads to chemotherapy failure during cancer treatment. The overexpression of ATP-binding cassette (ABC) transporters represents the major mechanism contributing to MDR. To date, no effective MDR modulator has been applied in clinic. Adagrasib (MRTX849), a specific inhibitor targeting KRAS G12C mutant, is currently under...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Berberine and alkaloids research
• Share to Cancer therapeutics and mechanisms
• Share to Drug Transport and Resistance Mechanisms